SM1-71

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SM1-71  纯度: 96.00%

SM1-71 是一种有效的 TAK1 抑制剂，Ki 值为 160 nM，同时可以共价抑制 MKNK2、MAP2K1/2/3/4/6/7、GAK、AAK1、BMP2K、MAP3K7、MAPKAPK5、GSK3A/B、MAPK1/3、SRC、YES1、FGFR1、ZAK (MLTK)、MAP3K1、LIMK1 和 RSK2。SM1-71 在体外抑制多种癌细胞系的增殖。

SM1-71

SM1-71 Chemical Structure

CAS No. : 2088179-99-9

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥820 In-stock
5 mg ￥800 In-stock
10 mg ￥1300 In-stock
25 mg ￥2500 In-stock
50 mg ￥4000 In-stock
100 mg ￥6500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SM1-71 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Covalent Screening Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines[1][2][3].

IC50 & Target

IC50: 0.8 nM (GAK), 0.8 nM (YES1), 2 nM (SRC), 4.4 nM (AAK1), 5.4 nM (LIMK1), 7.1 nM (BMP2K), 9.3 nM (MAP2K2), 10.4 nM (MAP2K1), 28.7 nM (MAP3K1), 48.3 nM (MAPK1), 107 nM (MAPK3)[1]
体外研究
(In Vitro)

SM1-71 (0.001-100 μM; 72 h) potently inhibits the proliferation of H23 and Calu-6 non-small cell lung cancer cell lines with a concentration-dependent manner[1].
SM1-71 (72 h) induces potent cytotoxicity with nanomolar values for GR50 and negative GRmax values in eight of 11 cancer cell lines[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: H23-KRASG12C and Calu-6-KRASQ61K cells
Concentration: 0.001, 0.01, 0.1, 1, 10, 100 μM
Incubation Time: 72 hours
Result: Inhibited proliferation of H23-KRASG12C and Calu-6-KRASQ61K cells with IC50s of 0.4 and 0.3 μM, respectively.

分子量

463.96

Formula

C24H26ClN7O
CAS 号

2088179-99-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (269.42 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1554 mL 10.7768 mL 21.5536 mL
5 mM 0.4311 mL 2.1554 mL 4.3107 mL
10 mM 0.2155 mL 1.0777 mL 2.1554 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.48 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.48 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Rao S, et, al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019 Jun 20; 26(6): 818-829.e9.

    [2]. Rao S, et, al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem. 2019 May 24;294(21):8664-8673.

    [3]. Tan L, et, al. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 Feb 1; 25(3): 838-846.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务